PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Bromocriptine use in the treatment of prostatic carcinoma
Article published in Urologia Polska 1982/35/3-4.

authors

Leszek Jeromin
Klinika Urologii Instytutu Chirurgii AM w Łodzi
Dyrektor Instytutu: doc. dr H. Zalech
Kierownik Kliniki: doc. dr hab. L. Jeromin

summary

It is thought that bromocriptine decreasing the serum prolactin level could have a favourable effect on oestrogen concentration in the serum of patients with prostatic carcinoma. Bromocriptine has only slight side effects.

references

  1. Bartsh W., Steins P., Becker H.: Hormone blood levels in patients with
  2. prostatic carcinoma and their relation to the type of carcinoma growth differen-
  3. tiation. Eur. Urol., 1977, 3, 47.
  4. Besser G. M.: Bromocriptine and the tubero-
  5. infundibular system: hyperprolactinemia. Triangel, 1978, 17, 33.
  6. Besser G. M.,
  7. Thorner M. O.: Bromocriptine in the treatment of the hyperprolactinaemia ? hy-
  8. pogonadim syndromes. Postgraduate Med. J., 1976, 52, 64.
  9. Clemans J. A., Shaar
  10. C. J., Smalstig E. B., Back N. J.: Inhibition of prolactin secretion by ergolines.
  11. Endocrinology, 1974, 94, 1171.
  12. Cooke L, Foley M., Lenlon E., Preston E., Mil-
  13. lar D., Jenkins A., Obiekwe B., McNeilly A., Parsons J., Kennedy G.: The treat­
  14. ment of puerperal lactation with bromocriptine. Postgraduate Med. J., 1976, 52,
  15. 75.
  16. Coune A., Smith P.: Clinical trial 2-bromo-alfa-ergocriptine (NSC-169774)
  17. in human prostatic cancer. Cancer Chemotherapy Reports, 1975, 59, 209
  18. De-
  19. lacre K. P. J., Debruyne F. M. J., Monen W. A.: Has bromocriptine o place in the
  20. treatment of the unstable bledder? Brit. J. Urol., 1978, 50, 169.
  21. Farnsworth
  22. W. E., Gonder H. J.: Prolactin and prostate cancer. Urology, 1977, 10, 33.
  23. Farjrar D. J., Pryor J. S.: The effect of bromocriptine in patients with benign
  24. prostatic hypertrophy. Brit. J. Urol., 1976, 48, 73.
  25. Fliickinger E.: Regulation
  26. der Prolactin-Secretion. Gynakologe, 1977, 10, 62.
  27. Fliickinger E.: Effects of bromocriptine on the hypothalamopituitary axis.
  28. Acta Endocr., Suppl. 216. 1978, 88, 111
  29. Gala R. R., Boss R. S.: Serum pro­
  30. lactin levels of rats under continous estrogen stimulation and 2 Br-alpha-Ergo-
  31. criptine (CB-154) injection (38800). Proc. Soc. Exp. Biol. Med., 1975, 149, 330.
  32. Hachmeister U.: Hyperplasia of prolactin cells after estrogen therapy in car­
  33. cinoma of the prostate. Verh. Dtsch. Gesellsch. Path., 1972, 56, 535.
  34. Hók-
  35. felt B.: Dopaminergic transmission and dopamine agonism. Acta Endocr., Suppl.
  36. 216. 1978, 88, 9. ?
  37. Jacobi G. H., Altwein J. E.: Bromocriptine, ein neues the-
  38. rapeutisches Prinzip beim Prostata-Adenom und -Karzinom. Dtsch. Med. Wschr.,
  39. 1978, 103, 827.
  40. Jacobi G. H., Kurth K. H., Altwein J. E.: Effect von Bromo-
  41. criptin beim Prostatakarzinom: Testosteronstoffwechsel in Abhangigkeit vom Dif-
  42. ferezirungsgrad. Urologe, 1979, 18, 91.
  43. Jacobi G. H., Sinterhauf K., Kurth
  44. K. H., Altwein J .E.: Bromocriptine and prostatic uptake of 3H-testosterone in
  45. vivo. J. Urol., 1978, 119, 240.
  46. Leblanc H., Lachelin G. C. L., Abu-Fadil S., Yen
  47. S. S. C: Effects of dopamine infusion on pituitary hormone secretion in humans.
  48. J. Clin. Endocr. Metab., 1976, 43, 668.
  49. Marinbach E. B., Are W. M.: Lecze­
  50. nie estrogenorezistentnych form raka predstatielnoj żelezy. Urol. Nefrol., 1974, 4,68.
  51. 0'Boyle P. J., Parson K. F.: Primary vesical sensory urgency. A clinical trial of bromocriptine. Brit. J. Urol., 1979, 51, 200.
  52. Olgaard K., Hagen C, Madsen S., Hummer L.: Lack of effect of prolactin inhibition by alpha-bromoergocriptine (CB-154) on plasma aldosterone in anephric and non-nephroctomized patients on regular haemodialysis. Acta Endocr., 1977, 85, 587.
  53. Pawlikowski M.: Attempt at pharmacological treatment of the pituitary tumor with bromocriptine. Endokr. Pol., 1978, 29, 413.
  54. Plumpton K., Morales A.: Levodopa in cancer of the prostate. J. Urol., 1975, 114, 482.
  55. Resnick M. I., Grayhack J. T.: Effect of 2-bromo-alpha-ergocriptine (CB-154) on estrogen indu-ced growth of the rat prostate. Invest. Urol., 1978, 15, 392.
  56. Sadoughi N., Raź­ni M., Bush I., Albin R., Guinan P.: Cancer of prostate. Relief of pain with levo-dopa. Urology, 1974, 4, 107.
  57. Stąpień H., Wolaniuk A., Pawlikowski M.: Effects of pimozide and bromocriptine an anterior pituitary cell proliferation. J. Neurol. Transmission, 1978, 42, 239.
  58. Strauch G., Valcke J. C, Mahoudeau J. A., Bri-caire H.: Hormonal changes induced by bromocriptine (CB-154) at the early stage of treatment. J. Clin. Endocrinol. Metab., 1977, 44, 588.
  59. Teter J.: Leki hor­monalne. Klinika i terapia. PZWL, Warszawa, 1979.
  60. Thorner M. O.: Dopa-mine is on important neurotransmitter in the autonomie nervous system. Lancet, 1975, 1, 662.
  61. Thorner M. O., Besser G. M.: Successful treatment of acrome-galy with bromocriptine. Postgraduate Med. J., 1976, 52, 71.